Article Details

Talquetamab Plus Daratumumab Generates High Response Rate in CD38-Refractory Myeloma

Retrieved on: 2022-06-12 20:50:52

Tags for this article:

Click the tags to see associated articles and topics

Talquetamab Plus Daratumumab Generates High Response Rate in CD38-Refractory Myeloma. View article details on hiswai:

Excerpt

As a human IgG1k monoclonal antibody targeting CD38 with a direct on-tumor ... Most patients were refractory to CD38 antibodies, namely 78.6% and ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up